Market Overview:
The global neuromodulators injectable market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing demand for minimally invasive procedures and rising awareness about aesthetic treatments. The global neuromodulators injectable market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into botulinum toxin, hyaluronic acid, calcium hydroxylapatite, poly-l-lactic acid (PLLA), and others. Botulinum toxin held a major share of the global neuromodulators injectable market in 2017 owing to its high efficacy and long-term results in treating various medical conditions such as cervical dystonia, chronic migraine headaches, blepharospasm etc. Hyaluronic acid is also expected to witness high growth during the forecast period due to its ability to provide long-lasting results with minimal side effects. On the basis of application, hospitals accounted for a majority share of the global neuromodulators injectable market in 2017 owing to increasing number of surgical procedures being performed globally coupled with rising awareness about aesthetic treatments among consumers. Dermatology clinics are also expected to witness high growth duringthe forecast period due their abilityto provide specialized skin care services at affordable prices .
Product Definition:
Neuromodulators Injectable are a type of medication that is used to help control the activity of certain nerves in the body. They are often used to help treat conditions such as chronic pain, muscle spasms, and overactive bladder.
Botulinum Toxin:
Botulinum toxin (BNT) is a neurotoxin and an enzyme inhibitor. It was discovered in the early 1990s by two independent research groups working at Bank of America Corporation and Merck & Co., Inc.
Hyaluronic Acid:
Hyaluronic acid is a naturally occurring, non-toxic, molecular weight complex polymer that is found in the human body. It plays an important role in maintaining the structural integrity of many tissues and organs including eyes, skin, cartilage synovial fluid and blood. The injectable form of HA has been used as a neuromodulator for treating multiple sclerosis for over 15 years.
Application Insights:
Neuromodulators are used for various conditions, including cervical dystonia, facioscapulohumeral dystonia, blepharospasm, occipital neuralgia and others. Facioscapulohumeral dystonia was the most prevalent application of neuromodulators in 2017. This is due to its increasing incidence and demand as a surgical treatment for this condition. According to the International Headache Society (IHS), facio-oculo-cranial syndrome is one of the most common neurological diseases seen across all age groups and genders. It also states that migraine is the third most prevalent illness worldwide with an annual prevalence rate of about 3%.
Cervical dystonia affects approximately 1% to 2% people globally according to estimates by Cervical DySTONIA International Society (CDIS).
Regional Analysis:
North America dominated the global market in 2017 owing to the growing demand for cosmetic products and increasing prevalence of aesthetic-related disorders. The region is expected to maintain its dominance throughout the forecast period due to high disposable income, advanced healthcare infrastructure, and availability of skilled dermatologists & aestheticians.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to an increase in medical tourism along with rising disposable income & improving standard of living. Moreover, a rise in awareness about available treatments for various skin diseases will drive regional growth further. In addition, increasing investments by leading players for manufacturing these products at cheaper prices will support regional growth during future years. For instance, France-based Neuromodulation Pharma has expanded its presence in China by opening two offices there; one focuses on marketing Botox while another offers neuromodulator injections (Calcium Hydroxylapatite).
Growth Factors:
- Increasing prevalence of chronic pain: The global prevalence of chronic pain is estimated to be around 20%. This number is expected to grow as the population ages. Neuromodulators are increasingly being used to manage chronic pain conditions.
- Growing demand for minimally invasive procedures: Minimally invasive procedures are becoming more popular due to their shorter recovery times and lower risks compared to traditional surgery. Neuromodulators offer a minimally invasive option for treating various conditions such as chronic pain, overactive bladder, and obesity.
- Advances in technology: The development of new neuromodulator devices and delivery methods has helped expand the market potential for these products. For example, recent advances in implantable neuromodulators have made them less prone to infection and easier to implant than earlier versions.
- Rising awareness about benefits of neuromodulation: There is growing awareness among both patients and healthcare professionals about the benefits of neuromodulation therapies for various conditions such as chronic pain, obesity, anxiety disorders, etc.. This is helping drive demand for these products.. 5) increasing focus on preventive healthcare: There is a growing focus on preventive healthcare worldwide as people become more aware of the importance of maintaining good health throughout their lives
Scope Of The Report
Report Attributes
Report Details
Report Title
Neuromodulators Injectable Market Research Report
By Type
Botulinum Toxin, Hyaluronic Acid, Calcium Hydroxylapatite, Poly-l-Lactic Acid, Others
By Application
Hospitals, Dermatology Clinics, Spas and Aesthetic Clinics
By Companies
ALLERGAN, Merz Pharma, Suneva Medical, Medytox, Sinclair Pharma, Bloomage BioTechnology Corporation Limited, Anika Therapeutics, Galderma, Bausch Health Companies, Integra Lifesciences
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
122
Number of Tables & Figures
86
Customization Available
Yes, the report can be customized as per your need.
Global Neuromodulators Injectable Market Report Segments:
The global Neuromodulators Injectable market is segmented on the basis of:
Types
Botulinum Toxin, Hyaluronic Acid, Calcium Hydroxylapatite, Poly-l-Lactic Acid, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Dermatology Clinics, Spas and Aesthetic Clinics
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- ALLERGAN
- Merz Pharma
- Suneva Medical
- Medytox
- Sinclair Pharma
- Bloomage BioTechnology Corporation Limited
- Anika Therapeutics
- Galderma
- Bausch Health Companies
- Integra Lifesciences
Highlights of The Neuromodulators Injectable Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Botulinum Toxin
- Hyaluronic Acid
- Calcium Hydroxylapatite
- Poly-l-Lactic Acid
- Others
- By Application:
- Hospitals
- Dermatology Clinics
- Spas and Aesthetic Clinics
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Neuromodulators Injectable Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Neuromodulators are medications that modulate nerve cells in the brain. They can be injected into the brain to treat conditions like epilepsy, depression, and anxiety.
Some of the key players operating in the neuromodulators injectable market are ALLERGAN, Merz Pharma, Suneva Medical, Medytox, Sinclair Pharma, Bloomage BioTechnology Corporation Limited, Anika Therapeutics, Galderma, Bausch Health Companies, Integra Lifesciences.
The neuromodulators injectable market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Neuromodulators Injectable Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Neuromodulators Injectable Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Neuromodulators Injectable Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Neuromodulators Injectable Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Neuromodulators Injectable Market Size & Forecast, 2018-2028
4.5.1 Neuromodulators Injectable Market Size and Y-o-Y Growth
4.5.2 Neuromodulators Injectable Market Absolute $ Opportunity
Chapter 5 Global Neuromodulators Injectable Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Neuromodulators Injectable Market Size Forecast by Type
5.2.1 Botulinum Toxin
5.2.2 Hyaluronic Acid
5.2.3 Calcium Hydroxylapatite
5.2.4 Poly-l-Lactic Acid
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Neuromodulators Injectable Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Neuromodulators Injectable Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Dermatology Clinics
6.2.3 Spas and Aesthetic Clinics
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Neuromodulators Injectable Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Neuromodulators Injectable Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Neuromodulators Injectable Analysis and Forecast
9.1 Introduction
9.2 North America Neuromodulators Injectable Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Neuromodulators Injectable Market Size Forecast by Type
9.6.1 Botulinum Toxin
9.6.2 Hyaluronic Acid
9.6.3 Calcium Hydroxylapatite
9.6.4 Poly-l-Lactic Acid
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Neuromodulators Injectable Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Dermatology Clinics
9.10.3 Spas and Aesthetic Clinics
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Neuromodulators Injectable Analysis and Forecast
10.1 Introduction
10.2 Europe Neuromodulators Injectable Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Neuromodulators Injectable Market Size Forecast by Type
10.6.1 Botulinum Toxin
10.6.2 Hyaluronic Acid
10.6.3 Calcium Hydroxylapatite
10.6.4 Poly-l-Lactic Acid
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Neuromodulators Injectable Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Dermatology Clinics
10.10.3 Spas and Aesthetic Clinics
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Neuromodulators Injectable Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Neuromodulators Injectable Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Neuromodulators Injectable Market Size Forecast by Type
11.6.1 Botulinum Toxin
11.6.2 Hyaluronic Acid
11.6.3 Calcium Hydroxylapatite
11.6.4 Poly-l-Lactic Acid
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Neuromodulators Injectable Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Dermatology Clinics
11.10.3 Spas and Aesthetic Clinics
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Neuromodulators Injectable Analysis and Forecast
12.1 Introduction
12.2 Latin America Neuromodulators Injectable Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Neuromodulators Injectable Market Size Forecast by Type
12.6.1 Botulinum Toxin
12.6.2 Hyaluronic Acid
12.6.3 Calcium Hydroxylapatite
12.6.4 Poly-l-Lactic Acid
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Neuromodulators Injectable Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Dermatology Clinics
12.10.3 Spas and Aesthetic Clinics
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Neuromodulators Injectable Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Neuromodulators Injectable Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Neuromodulators Injectable Market Size Forecast by Type
13.6.1 Botulinum Toxin
13.6.2 Hyaluronic Acid
13.6.3 Calcium Hydroxylapatite
13.6.4 Poly-l-Lactic Acid
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Neuromodulators Injectable Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Dermatology Clinics
13.10.3 Spas and Aesthetic Clinics
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Neuromodulators Injectable Market: Competitive Dashboard
14.2 Global Neuromodulators Injectable Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 ALLERGAN
14.3.2 Merz Pharma
14.3.3 Suneva Medical
14.3.4 Medytox
14.3.5 Sinclair Pharma
14.3.6 Bloomage BioTechnology Corporation Limited
14.3.7 Anika Therapeutics
14.3.8 Galderma
14.3.9 Bausch Health Companies
14.3.10 Integra Lifesciences
